The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000889358p
Ethics application status
Help: Ethics application status
Not yet submitted
Date submitted
Help: Date submitted
3/07/2026
Date registered
Help: Date registered
17/07/2026
Date last updated
Help: Date last updated
17/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
17/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Can sensory massage balls reduce chemotherapy-induced peripheral neuropathy symptoms and improve the quality of life in adults receiving chemotherapy?
Scientific title
Rolling Towards Relief: A pilot randomised controlled trial evaluating the feasibility, safety and efficacy of self-guided sensory massage ball use for chemotherapy-induced peripheral neuropathy in adults receiving or recently completing chemotherapy, measured by CIPN symptom severity, quality of life, balance, strength and dexterity.
Additional trial identifiers [1] 317794 0
Protocol Number: RTR-CIPN V1.2
Additional trial identifiers [2] 317795 0
Sponsor-issued identifier: RTR-CIPN
Universal Trial Number (UTN)
U1111-1343-3513
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 342704 0
Cancer treatment-related neuropathy 342705 0
Condition category
Condition code
Cancer 338845 338845 0 0
Any cancer
Neurological 338846 338846 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Arm 1: Sensory Massage Ball Intervention
Participants will receive a set of sensory ("spikey") massage balls of varying firmness and texture, together with written instructions and video guidance (in development). Following baseline assessment and randomisation, participants will undertake self-directed use of the massage balls at home for 8 weeks. Participants will record usage frequency, duration and symptoms in a daily log. A 1 hour familiarisation session will be provided by trained study personnel. Logs will be reviewed at Week 8 and Week 16. Participants will be instructed to contact the research team if adverse events or worsening symptoms occur.

Materials
Sensory massage balls
Participant information sheets
Instructional videos
Daily logbook

Mode of delivery
Initial face-to-face instruction
Individual home-based practice

Duration
Daily self-guided use over 8 weeks

Adherence
Daily participant logs reviewed at Week 8 and Week 16.
Intervention code [1] 334805 0
Rehabilitation
Intervention code [2] 334806 0
Lifestyle
Intervention code [3] 334807 0
Other interventions
Description of the comparator or control
Arm 2: Usual Care
Participants randomised to usual care will receive publicly available physical activity guidance https://www.cancercouncil.com.au/cancer-information/living-well/after-cancer-treatment/taking-control-of-your-health/being-physically-active/. Upon completion of Week 8 testing and provided that no intervention-related adverse events are identified, they will receive the sensory massage ball set and guidance on its use.
Control group
Active

Outcomes
Primary outcome [1] 346051 0
Feasibility of intervention delivery (assessed through intervention adherence and participant completion rates)
Timepoint [1] 346051 0
Throughout the 8-week intervention period and at intervention completion.
Primary outcome [2] 346052 0
Safety of sensory massage ball intervention
Timepoint [2] 346052 0
Baseline Week 8 (post study commencement) Week 16 follow-up
Primary outcome [3] 346256 0
Recruitment and retention rates
Timepoint [3] 346256 0
Recruitment rate: Assessed throughout the recruitment period and reported at the end of recruitment. Retention rate: Assessed at completion of the 8-week intervention and post-intervention assessment.
Secondary outcome [1] 464441 0
Chemotherapy-induced peripheral neuropathy symptom severity
Timepoint [1] 464441 0
Baseline Week 8 (Post study commencement) Week 16 (follow-up)
Secondary outcome [2] 464442 0
Quality of Life
Timepoint [2] 464442 0
Baseline Week 8 (Post study commencement) Week 16 (follow-up)
Secondary outcome [3] 464445 0
Hand Strength
Timepoint [3] 464445 0
Baseline Week 8 (Post study commencement) Week 16 (follow-up)
Secondary outcome [4] 464446 0
Manual Dexterity
Timepoint [4] 464446 0
Baseline Week 8 (Post study commencement) Week 16 (follow-up)
Secondary outcome [5] 464447 0
Participant Acceptability - Assessed using post-intervention questionnaires and interview data exploring participants' satisfaction with, perceived suitability of, and willingness to engage with the intervention.
Timepoint [5] 464447 0
Week 8 (post study commencement)
Secondary outcome [6] 464835 0
Participant Experience
Timepoint [6] 464835 0
Week 8 (post intervention completion)

Eligibility
Key inclusion criteria
Adults aged 18 years or older
Currently receiving chemotherapy, or completed chemotherapy within the previous month
Receiving care through Tweed Valley Hospital
Current symptoms consistent with CIPN
Clinically diagnosed (Grade 1 CTCAE) or self-identified CIPN
Medically cleared for participation
Adequate English language proficiency
Able to provide informed consent
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Unable to provide informed consent
No current CIPN symptoms
Chemotherapy completed more than one month prior to baseline testing
Previous chemotherapy treatment for prior cancer diagnosis
Other neuropathies (e.g., diabetic neuropathy)
Conditions affecting peripheral nerve function (e.g., lymphoedema, peripheral artery disease)
Unwilling to undergo randomisation

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment will be achieved through central, off-site randomisation. The randomisation sequence will be generated by a member of the research team not involved in participant recruitment or enrolment. Group allocation will be concealed until participants have completed baseline assessments and been enrolled in the study.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple computer-generated randomisation.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
This is a pilot feasibility randomised controlled trial and is not powered to detect definitive between-group efficacy effects. A target sample of 20–30 participants has been selected to assess feasibility, safety, recruitment, retention, adherence, acceptability and variability in outcome measures to inform the design of a future definitive trial. Feasibility outcomes, including recruitment, retention, adherence, intervention completion, data completeness and adverse events, will be summarised descriptively using counts, percentages, means, standard deviations, medians, interquartile ranges and ranges as appropriate.
Secondary clinical outcomes will include CIPN symptom severity measured using the EORTC QLQ-CIPN20, quality of life measured using the EORTC QLQ-C30, balance assessed using timed balance tests, handgrip strength assessed using a dynamometer, and manual dexterity assessed using the Purdue Pegboard assessment. Outcomes will be summarised by group at baseline, Week 8 and Week 16. The main exploratory between-group comparison will examine change from baseline to Week 8, as the usual care group may receive the intervention after Week 8 if no adverse events or negative effects are observed. Within-group changes and between-group differences in change scores will be reported with effect sizes and 95% confidence intervals. Where appropriate, ANOVA/ANCOVA or repeated-measures models will be used; non-parametric alternatives such as Friedman’s test will be used if assumptions are not met. Missing data will be described and handled using complete-case analysis, multiple imputation or sensitivity analyses as appropriate. Qualitative interview data will be analysed using inductive thematic analysis. Analyses will be conducted using SPSS or R, with exploratory statistical significance set at p<0.05.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 29799 0
The Tweed Hospital - Tweed Heads
Recruitment hospital [2] 29800 0
Southern Cross University Health Clinic - Lismore
Recruitment postcode(s) [1] 46145 0
2485 - Tweed Heads
Recruitment postcode(s) [2] 46146 0
2480 - Lismore

Funding & Sponsors
Funding source category [1] 322338 0
Government body
Name [1] 322338 0
NNSWLHD
Country [1] 322338 0
Australia
Funding source category [2] 322413 0
Other Collaborative groups
Name [2] 322413 0
NNSW Academic Health Alliance CReSeG Funding Scheme
Country [2] 322413 0
Australia
Primary sponsor type
University
Name
Southern Cross University
Address
Country
Australia
Secondary sponsor category [1] 325255 0
Government body
Name [1] 325255 0
Northern NSW Local Health District
Address [1] 325255 0
Country [1] 325255 0
Australia
Other collaborator category [1] 284015 0
University
Name [1] 284015 0
Griffith University
Address [1] 284015 0
Country [1] 284015 0
Australia
Other collaborator category [2] 284016 0
University
Name [2] 284016 0
Southern Cross University
Address [2] 284016 0
Country [2] 284016 0
Australia
Other collaborator category [3] 284017 0
Hospital
Name [3] 284017 0
Tweed Valley Hospital
Address [3] 284017 0
Country [3] 284017 0
Australia

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 320841 0
North Coast NSW Human Research Ethics Committee
Ethics committee address [1] 320841 0
Ethics committee country [1] 320841 0
Australia
Date submitted for ethics approval [1] 320841 0
24/07/2026
Approval date [1] 320841 0
Ethics approval number [1] 320841 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151806 0
A/Prof Siddhartha Baxi
Address 151806 0
Site Name: Tweed Valley Hospital Street Address: 771 Cudgen Road Suburb/Town: Cudgen State: NSW Postcode: 2487
Country 151806 0
Australia
Phone 151806 0
+61 2 6677 3065
Fax 151806 0
Email 151806 0
Contact person for public queries
Name 151807 0
A/Prof Kellie Toohey
Address 151807 0
Southern Cross University, Locked Mail Bag 4, Coolangatta QLD 4225
Country 151807 0
Australia
Phone 151807 0
+61411019992
Fax 151807 0
Email 151807 0
Contact person for scientific queries
Name 151808 0
A/Prof Kellie Toohey
Address 151808 0
Southern Cross University, Locked Mail Bag 4, Coolangatta QLD 4225
Country 151808 0
Australia
Phone 151808 0
+61411019992
Fax 151808 0
Email 151808 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires a scientifically sound proposal or protocol
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Studies testing whether findings can be repeated or confirmed
When can requests for individual participant data be made (start and end dates)?
From:
At the end of the study
To:
A finite period of: 5 years
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
Yes: Analyses related to the study objectives and secondary research where approved by the investigators.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.